Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):571–573. doi: 10.1128/aac.39.2.571

Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections.

N C Karyotakis 1, M C Dignani 1, R Hachem 1, E J Anaissie 1
PMCID: PMC162585  PMID: 7726538

Abstract

Candida lusitaniae and Trichosporon beigelii may cause life-threatening infections in the immunocompromised host and may be resistant to amphotericin B. We assessed the activities of a new triazole, D0870, against one T. beigelii and four C. lusitaniae strains, in comparison with those of fluconazole and amphotericin B. Immunosuppressed CF1 mice, intravenously infected with each fungal strain, received 3 days of therapy with oral D0870 (5 or 25 mg/kg of body weight daily), fluconazole (5 to 50 mg/kg daily), or parenteral amphotericin B (1 or 2 mg/kg daily). Survival was significantly prolonged and kidney fungus titers were reduced in mice treated with D0870 compared with untreated mice (P < or = 0.05). Treatment with D0870 was significantly more effective than that with amphotericin B or fluconazole in animals infected with two of the C. lusitaniae strains and equally effective for the remaining two C. lusitaniae strains and the T. beigelii strain. Fluconazole and amphotericin B failed to improve the survival of mice infected with one and two C. lusitaniae strains, respectively. D0870 was active against all the organisms tested, including those resistant to fluconazole and amphotericin B.

Full Text

The Full Text of this article is available as a PDF (170.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anaissie E., Bodey G. P., Kantarjian H., Ro J., Vartivarian S. E., Hopfer R., Hoy J., Rolston K. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 1989 May-Jun;11(3):369–378. doi: 10.1093/clinids/11.3.369. [DOI] [PubMed] [Google Scholar]
  2. Anaissie E., Paetznick V., Bodey G. P. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother. 1991 Aug;35(8):1641–1646. doi: 10.1128/aac.35.8.1641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Atkinson B. A., Bocanegra R., Colombo A. L., Graybill J. R. Treatment of disseminated Torulopsis glabrata infection with DO870 and amphotericin B. Antimicrob Agents Chemother. 1994 Jul;38(7):1604–1607. doi: 10.1128/aac.38.7.1604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blinkhorn R. J., Adelstein D., Spagnuolo P. J. Emergence of a new opportunistic pathogen, Candida lusitaniae. J Clin Microbiol. 1989 Feb;27(2):236–240. doi: 10.1128/jcm.27.2.236-240.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clemons K. V., Hanson L. H., Stevens D. A. Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob Agents Chemother. 1993 May;37(5):1177–1179. doi: 10.1128/aac.37.5.1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Clemons K. V., Stevens D. A. Utility of the triazole D0870 in the treatment of experimental systemic coccidioidomycosis. J Med Vet Mycol. 1994;32(4):323–326. doi: 10.1080/02681219480000411. [DOI] [PubMed] [Google Scholar]
  7. Hadfield T. L., Smith M. B., Winn R. E., Rinaldi M. G., Guerra C. Mycoses caused by Candida lusitaniae. Rev Infect Dis. 1987 Sep-Oct;9(5):1006–1012. doi: 10.1093/clinids/9.5.1006. [DOI] [PubMed] [Google Scholar]
  8. Haupt H. M., Merz W. G., Beschorner W. E., Vaughan W. P., Saral R. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis. 1983 Feb;147(2):199–203. doi: 10.1093/infdis/147.2.199. [DOI] [PubMed] [Google Scholar]
  9. Karyotakis N. C., Anaissie E. J., Hachem R., Dignani M. C., Samonis G. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis. 1993 Nov;168(5):1311–1313. doi: 10.1093/infdis/168.5.1311. [DOI] [PubMed] [Google Scholar]
  10. Merz W. G. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol. 1984 Dec;20(6):1194–1195. doi: 10.1128/jcm.20.6.1194-1195.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Peng T., Galgiani J. N. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother. 1993 Oct;37(10):2126–2131. doi: 10.1128/aac.37.10.2126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ryley J. F., McGregor S., Wilson R. G. Activity of ICI 195,739--a novel, orally active bistriazole--in rodent models of fungal and protozoal infections. Ann N Y Acad Sci. 1988;544:310–328. doi: 10.1111/j.1749-6632.1988.tb40416.x. [DOI] [PubMed] [Google Scholar]
  13. Walsh T. J., Melcher G. P., Rinaldi M. G., Lecciones J., McGough D. A., Kelly P., Lee J., Callender D., Rubin M., Pizzo P. A. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990 Jul;28(7):1616–1622. doi: 10.1128/jcm.28.7.1616-1622.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yamada H., Tsuda T., Watanabe T., Ohashi M., Murakami K., Mochizuki H. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob Agents Chemother. 1993 Nov;37(11):2412–2417. doi: 10.1128/aac.37.11.2412. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES